We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Teva Pharmaceutical has announced that the FDA has granted tentative approval for the company's abbreviated new drug application (ANDA) to market its generic version of Novartis' hypertension treatment Lotrel (Amlodipine Besylate and Benazepril HCl) Capsules in 2.5 mg base/10 mg, 5 mg base/10 mg, 5 mg base/20 mg and 10 mg base/20 mg dosages.
Pharmaceutical groups AstraZeneca and Abbott announced that they will jointly develop and commercialize in the United States a fixed-dose combination product containing two lipid-regulating agents.
Actavis Group has submitted an improved proposal to Croation drugmaker Pliva and has served a notice of intention to publish a public offer under Croatian Takeover Law.
Pharmaceuticals Instruments industry news provided by Financial News USA. Biotechnology company Antigenics Inc. said Monday it has expanded a license and supply agreement with a unit of GlaxoSmithKline Plc. (NYSE:GSK)
Neose Technologies, Inc. today provided an update on its clinical development program for NE-180, the Company's long-acting, GlycoPEGylated erythropoietin for the treatment of anemia.
Ipsen and Medicis today announced that they will not pursue an agreement for the commercialization of Ipsen's botulinum toxin product, Reloxin, outside of the United States, Canada and Japan.
Johnson & Johnson, a health care company, announced that OrthoNeutrogena, a division of Ortho-McNeil Pharmaceutical, Inc., a Johnson & Johnson company, has purchased privately held biotechnology company Colbar LifeScience Ltd., specializing in reconstructive medicine and tissue engineering.